期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血管紧张素Ⅱ受体阻滞剂对PPAR-γ的激活作用 被引量：2

AngiotensinⅡ receptor blocker induces the activation of peroxisome proliferator-activated receptor gamma
下载PDF
导出
摘要 目的通过观察血管紧张素Ⅱ受体阻滞剂(ARB)对过氧化物酶体增殖物激活受体(PPAR)的作用,探讨其改善糖脂代谢的机制。方法用双荧光素酶基因报告系统构建PPARs配体筛选系统检测荧光素酶活性,以反映厄贝沙坦及替米沙坦对PPAR启动子激活程度。应用RT-PCR测定厄贝沙坦及替米沙坦PPAR-γmRNA表达活性。结果厄贝沙坦及替米沙坦均可呈剂量及时间依赖性增强COS-7细胞PPAR-γ启动子表达活性,呈剂量依赖性增强3T3-L1细胞PPAR-γmRNA表达。结论可能为PPAR-γ激动剂通过激活PPARs系统来发挥其改善代谢的作用。 Objective To observe the effect of angiotensin Ⅱ receptor blockers（ARBs）on peroxisome proliferator-activated receptor gamma（PPAR-γ）and to explore its mechanism for improving glucose and lipids metabolism.Methods Dual-luciferase gene reporting system was used to reflect PPAR-γ promoter activation by irbesartan and telmisartan.RT-PCR was used to reflect PPAR-γ mRNA by activation of irbesartan and telmisartan.Results Irbesartan and telmisartan may increase COS-7 cells PPAR-γ promoter expression and increase 3T3-L1 cells PPAR-γ mRNA expression in dose and time-dependent manners.Conclusions ARB may activate PPARs system to play a role in improving the glucose and lipids metabolism.
作者 荆丹清 尹士男 母义明
机构地区 解放军总医院第一附属临床医院内分泌科 解放军总医院内分泌科
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2008年第6期375-378,共4页 Chinese Journal of Diabetes
关键词 过氧化物酶体增殖物激活受体 厄贝沙坦 替米沙坦 Peroxisome proliferation-activated receptor Telmisartan Irbesartan
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献9

  • 1Gasparo M,Catt KJ,Inagami T,et al.International union of phar-macology,ⅩⅩⅢ:the angiotensin Ⅱ receptors.Pharmacol Rev,2000,52:415-472.
  • 2Miura Y,Yamamoto N,Tsunekawa S,et al.Replacement of val-sartan and candesartan by telmisartan in hypertensive patients with type2 diabetes.Diabetes care,2005,28:757-758.
  • 3Henriksen EJ,Jacob S,Kinnick TR,et al.Selective angiotensin Ⅱreceptor antagonism reduces insulin resistance in obese Zucker rats.Hypertension,2001,38:884-890.
  • 4Dahlof B,Devereux RB,Kjeldsen SE,et al.Cardiovascular mor-bidity and mortality in the Losartan Intervention for endpoint re-duction in hypertension study(LIFE):a randomized trial against atenolol.Lancet,2002,359 ; 995-1003.
  • 5Julius S,Kjeldsen SE,Weher M,et al.Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomized trial.Lancet,2004,363:2022-2031.
  • 6Schupp M,Clasen R,Unger T.Angiotensin type 1 receptor block-ers induce Peroxisome Proliferator-Activated Receptor-activity.Circulation,2004,109:2054-2057.
  • 7Schupp M,Clemenz M,Gineste R,et al.Molecular characteriza-tion of new selective Peroxisome Proliferator-Activated Receptor modulators with angiotensin receptor blocking activity.Diabetes,2005,54 ; 3442-3452.
  • 8Jankea J,Schuppb M,Engelia S,et al.Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxi-some proliferator-activated receptor-γ activation.Hypertension,2006,24:1809-1816.
  • 9Lehmano JM,Moore LB,Smith-Oliver TA,et al.An antidiabetie.thiazolidinedione is a high affinity ligand for peroxisome prolifera-tor activated receptorγ,(PPART).J Biol Chem,1995,270:12953-12956.

同被引文献38

  • 1那开宪,余平,罗晓.血管紧张素Ⅱ受体阻滞剂的临床应用[J].中国临床医生杂志,2006,34(1):51-53. 被引量：7
  • 2陈名道.糖尿病与冠心病——同源病,等危症?[J].中华内分泌代谢杂志,2006,22(1):4-6. 被引量：53
  • 3栾旭.血管紧张素转换酶抑制剂联合血管紧张素II受体阻滞剂治疗糖尿病肾病的临床研究[J].中国临床药理学与治疗学,2006,11(6):706-708. 被引量：2
  • 4De Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology, X X Ⅲ: the angiotensin Ⅱ: receptors. Pharmacol Rev, 2000,52:415-472.
  • 5Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenotol. Lancet, 2002,359:995-1003.
  • 6Henriksen EJ, Jacob S, Kinnick TR, et al. Selective angiotensin Ⅱ receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension, 2001,38:884-890.
  • 7Janke J, Engeli S, Gorzelniak K, et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes, 2002,51:1699-1707.
  • 8Julius S, Kjeldsen SE, Weher M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet,2004,363 : 2022-2031.
  • 9Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med, 1996,334:374-381.
  • 10Zanella MT, Kohlmann O Jr, Ribeiro AB. Treatment of obesity, hypertension and diabetes syndrome. Hypertension, 2001,38 : 705- 708.

引证文献2

二级引证文献4

中国糖尿病杂志
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部